Skip to content

Study · Measured the body's own peptide · 2020

1 result

CD-1db/db mice: A novel type 2 diabetic mouse model with progressive kidney fibrosis.

Mizunuma Y, Kanasaki K, Nitta K, Nakamura Y, Ishigaki Y, Takagaki Y, Kitada M, Li S, Liu H, Li J, Usui I, Aso Y, Koya D

Journal of diabetes investigation3 Jul 2020Cited by 14 (Europe PMC)

PMID32472621 (opens in a new tab)PMCIDPMC7610117 (opens in a new tab)DOI10.1111/jdi.13311 (opens in a new tab)PepBankPUB-32472621
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Other

    In a CD-1 db/db mouse model of diabetic kidney fibrosis, thymosin β4 levels were lower in CD-1 mice.

    In plain wordsIn mice, the body's own thymosin β4 levels were lower in a diabetic CD-1 mouse strain.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseTβ4 levels in CD-1 mice
    Study

    mousen: not reported in source

    CD-1 db/db mice
    Outcome group
    Inflammation markers · Metabolic and weight

    Source sentences

    Summary
    Thymosin β4 levels were also lower in CD-1 mice.
    1 context sentence
    Summary · context
    The gene expression of prolyl oligopeptidase, the enzyme essential for antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline production from thymosin β4, was significantly lower in the CD-1 mice.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.